Article
Pharmacology & Pharmacy
Bei Jin, Luo Yang, Qianyun Ye, Jingxuan Pan
Summary: Hepatic metastasis is a common and poorly treated cause of death in uveal melanoma (UM) patients. The mechanism underlying liver metastasis remains unknown. This study suggests that decapping scavenger enzymes (DCPS) impact ferroptosis by regulating mRNA decay during the metastatic colonization of UM cells to liver. Inhibition of DCPS induces gene transcript alteration and ferroptosis by reducing the mRNA turnover of GLRX. Inhibition of DCPS also eliminates cancer stem-like cells in UM and hampers the growth and proliferation of UM cells both in vitro and in vivo. Additionally, targeting DCPS diminishes hepatic metastasis of UM cells, providing a potential target for metastatic colonization in UM.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Oncology
Prisca Bustamante, Leo Piquet, Solange Landreville, Julia Burnier
Summary: Uveal melanoma is an intraocular tumor that tends to metastasize to the liver. Despite identifying early driver mutations, the process of UM metastasis remains incompletely understood. A better understanding of genetic, molecular, and environmental factors could lead to new approaches for UM treatment.
SEMINARS IN CANCER BIOLOGY
(2021)
Review
Oncology
Anna Hagstrom, Ruba Kal Omar, Pete A. Williams, Gustav Stalhammar
Summary: This study found that melatonin can inhibit the growth and metastasis of cancer cells, enhance immune system functions, and have anti-inflammatory effects. It may also enhance the efficacy of cancer treatments such as immunotherapy and chemotherapy. Oral melatonin supplementation has shown promising results in patients with other forms of cancer, and may have potential benefits for uveal melanoma.
Review
Biotechnology & Applied Microbiology
Marlana Orloff, Rino Seedor, Takami Sato
Summary: Uveal melanoma's response to immune checkpoint inhibition is disappointing, but bi-specific fusion protein therapies have shown potential for successful treatment.
CANCER GENE THERAPY
(2022)
Review
Oncology
Dominic Lapadula, Jeffrey L. Benovic
Summary: Uveal melanoma is a deadly eye cancer with no FDA-approved standard of care for metastatic disease. Mutations in the G(q/11) signaling pathway drive the pathogenesis of this cancer. Treatment of the primary tumor is often effective, but a high percentage of patients develop metastasis, most commonly to the liver.
Review
Ophthalmology
Elina S. Rantala, Micaela M. Hernberg, Sophie Piperno-Neumann, Hans E. Grossniklaus, Tero T. Kivela
Summary: Treatment of primary intraocular uveal melanoma has advanced significantly, but the risk of distant metastases remains high. There is no consensus on surveillance, staging, and treatment of disseminated disease, making it difficult to improve survival rates. Solving these issues is the key to curing metastatic uveal melanoma.
PROGRESS IN RETINAL AND EYE RESEARCH
(2022)
Article
Cell Biology
Wenchuan Zhou, Jing Li
Summary: In this study, we investigated immune cell infiltration and survival-related genes in uveal melanoma (UVM) patients, and constructed a predictive model. Our analysis revealed the importance of immune-related genes in the progression of UVM.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Medicine, General & Internal
Abin Sajan, Samuel Fordyce, Andrew Sideris, Connie Liou, Zeeshan Toor, John Filtes, Venkatesh Krishnasamy, Noor Ahmad, Stephen Reis, Sidney Brejt, Asad Baig, Shaheer Khan, Michael Caplan, David Sperling, Joshua Weintraub
Summary: Uveal melanoma is a common form of ocular melanoma, accounting for 85% of all cases. Its pathophysiology and treatment options differ from cutaneous melanoma. The prognosis for uveal melanoma with metastases is poor, with a one-year survival rate of only 15%. This review focuses on locoregional treatment options for hepatic uveal melanoma metastases, including percutaneous hepatic perfusion, immunoembolization, chemoembolization, thermal ablation, and radioembolization.
Review
Ophthalmology
Haixia Bai, Jacobus J. Bosch, Ludwig M. Heindl
Summary: Uveal melanoma, the most common primary intraocular cancer in adults, is typically confined to the choroid. Current treatment options include radiation therapy, laser therapy, local resection, and enucleation, with the best outcomes achieved through combination therapies. However, half of the patients develop metastatic disease without effective treatment options. Recently, new treatment modalities have emerged to improve tumor control and reduce adverse events. This review provides an overview of current clinical treatments and new therapeutic perspectives for uveal melanoma.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Oncology
Min-Yun Cai, Yue-Li Xu, Hua Rong, Hai Yang
Summary: PALMD expression is associated with poor prognosis in uveal melanoma (UM) and plays a critical role in controlling UM cell invasion and migration. ZNF263 regulates PALMD transcription and impacts UM metastasis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Alexej Ballhausen, Elizabeth Urias, Stephen K. Gruschkus, Michelle Williams, Maura S. Glover, Yong Qin, Dan S. Gombos, Sapna P. Patel
Summary: The study found that in uveal melanoma Class 1A patients, those with stage III disease and/or large COMS size are at elevated risk for metastasis. Combined clinical decision-making using AJCC stage and COMS size can have a significant impact on improving risk stratification and adapting follow-up intervals for Class 1A UM patients.
Article
Oncology
Wojtek Drabarek, Job van Riet, Josephine Q. N. Nguyen, Kyra N. Smit, Natasha M. van Poppelen, Rick Jansen, Eva Medico-Salsench, Jolanda Vaarwater, Frank J. Magielsen, Tom Brands, Bert Eussen, Thierry. P. P. van den Bosch, Robert M. Verdijk, Nicole C. Naus, Dion Paridaens, Annelies de Klein, Erwin Brosens, Harmen J. G. van de Werken, Emine Kilic, Rotterdam Ocular Melanoma Study Grp
Summary: This study describes the clinical and genetic characteristics of a cohort of 146 SF3B1-mutated UM, finding that SF3B1-mutated UM exhibit early- and late-onset metastatic disease without distinguishing biomarkers, with largest basal tumor diameter possibly associated with early metastasis. Analysis of gene expression and aberrant transcripts revealed an association between ABHD6 expression and early-onset metastatic SF3B1, providing potential prognostic indicators and therapeutic targets for SF3B1-mutated UM.
Article
Oncology
Aaron B. Beasley, Daniel P. de Bruyn, Leslie Calapre, Zeyad Al-Ogaili, Timothy W. Isaacs, Jacqueline Bentel, Anna L. Reid, Roy S. Dwarkasing, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Erwin Brosens, Annelies de Klein, Fred K. Chen, Emine Kilic, Elin S. Gray
Summary: This study demonstrates the potential of ctDNA monitoring as a biomarker for the early detection of metastasis and therapeutic response in uveal melanoma patients. It shows that ctDNA levels are predictive of overall survival and may be used for monitoring treatment response.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tatjana Seitz, Nora John, Judith Sommer, Peter Dietrich, Wolfgang E. Thasler, Arndt Hartmann, Katja Evert, Sven A. Lang, Anja Bosserhoff, Claus Hellerbrand
Summary: Hepatic metastasis is a critical factor for cancer-related mortality. It has been found that fibroblast growth factor 9 (FGF9) released by hepatic stellate cells (HSCs) promotes the proliferation of uveal melanoma (UM) cells, indicating FGF9 as a potential therapeutic target for hepatic metastasis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Ogul E. Uner, Thonnie Rose O. See, Eszter Szalai, Hans E. Grossniklaus, Gustav Stalhammar
Summary: The study found that BAP1 mutations in uveal melanoma occur early in tumor growth, typically appearing in the initial stages, and coincide with the seeding of micrometastases.
SCIENTIFIC REPORTS
(2021)